Articles

The findings of the current study suggest that patients with rheumatoid arthritis (RA) who achieve low disease activity with subcutaneous tocilizumab plus methotrexate (MTX) may potentially discontinue MTX and maintain disease control with tocilizumab monotherapy. Read More ›

The findings of this study showed that patients with rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) reported clinically meaningful improvements in patient-reported outcomes (PROs) with all 3 treatment regimens (tofacitinib monotherapy, tofacitinib plus MTX, and adalimumab plus MTX). PROs were comparable between tofacitinib plus MTX and adalimumab plus MTX therapies, with combination therapy numerically higher than tofacitinib monotherapy. Read More ›

In the open-label extension phase of the phase 3 MONARCH trial, patients switching from monotherapy with adalimumab 40 mg to open-label monotherapy with sarilumab 200 mg every 2 weeks demonstrated improvements in rheumatoid arthritis (RA) signs and symptoms and physical function that were numerically similar to patients who were initially randomized to sarilumab 200 mg every 2 weeks. Read More ›

Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation. Read More ›

A quantitative analysis revealed substantially different activity profiles for ibrutinib and chlorambucil in the circulating cells during the first year of treatment in patients with chronic lymphocytic leukemia (CLL). Read More ›

This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor. Read More ›

This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL). Read More ›

CALGB 10404, a randomized phase 2 study, compares different fludarabine chemoimmunotherapy regimens in patients with non-del(11q) chronic lymphocytic leukemia (CLL). Read More ›

GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib. Read More ›

This retrospective cohort study examines the use and efficacy of ibrutinib in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter transformation. Read More ›